(Incorporated in the Cayman Islands)

Established in Singapore in 2009, we are a customer-centric science-backed aesthetics services provider. We prioritize delivering an unparalleled premium experience for our customers by emphasizing safety, privacy and patient comfort. In addition to the market’s prevailing medi-aesthetics treatments, our suite of science-backed aesthetics services also includes bio-regenerative treatments and other advanced therapies. Our services are rendered through five strategically located clinics staffed by experienced doctors and equipped with advanced medical devices. Our mission is to elevate the overall well-being of our customers by offering personalized anti-aging and longevity healthcare and aesthetics solutions. In the 16 years since the commencement of our business, we have served more than 300,000 customers.

We offer a broad range of non-surgical minimally invasive treatments to our customers in our clinics. The technological concept, procedures and equipment used to administer such treatments are carefully selected by our experienced doctors. Our treatments are designed based on scientific evidence and delivered by personnel with medical knowledge, training and experience.

Our services can be classified into two categories: bio-regenerative treatments and medi-aesthetics treatments. Bio-regenerative treatments are generally marketed as aesthetics solutions at the forefront of our industry. They are grounded on the skin’s natural ability to regenerate and repair itself through the use of natural bio-cosmeceutical products such as plant-based exosomes and stem cells as skin boosters. (Note: Plant-based exosomes are tiny naturally occurring vesicles released by cells that act as messengers, carrying proteins, lipids, and genetic material to influence the behavior of other cells.) Medi-aesthetics treatments are solutions delivered through the use of technologies that are regarded as the industry norm, including non-invasive procedures such as laser treatments and other energy treatments – as well as minimally invasive procedures using botox and other chemical ingredients.

Note: Net income and revenue are in U.S. dollars for the12 months that ended June 30, 2025.

(Note: Regenique Group filed its F-1 on Oct. 31, 2025, and disclosed the terms for its IPO: 2 million shares at a price range of $4.00 to $5.00 to raise $9 million, if priced at the $4.50 mid-point of its range.))